At YGION, we harness the power of the body’s own immune system to trigger robust and durable response against cancer.
Our approach is rooted in translating deep biological insights into precisely engineered therapies that activate immunity where it matters most.
YGION is a clinical‑stage company, with its lead product YG‑01 currently in clinical development for glioblastoma.
Team
Founded in 2022 by a group of scientific innovators, YGION has grown into an international, multidisciplinary team dedicated to tackling the challenges of cancer genomics and immunotherapy.
Wolfgang Fischl, PhD
Chief Executive Officer, Co-Founder
Georg Casari, PhD
Chief Operating Officer, Co-Founder
Sophie Zettl, PhD
Chief Business Officer
Anna-Dorothea Gorki, PhD
Chief Scientific Officer
News
YGION’s scientific team attends EACR 2026
CSO Dr Anna-Dorothea Gorki and Scientist Dr Vanessa Mühlgrabner will be attending the 2026 Annual Congress of the European Association for Cancer Research on June 8th-11th in Budapest. The team will be...
YGION Biomedical attends leading Partnering Conferences
CBO, Dr Sophie Zettl will be attending key partnering and investment conferences this Spring to discuss collaboration and investment opportunities at YGION Biomedical. On March 23-26th 2026, YGION will be attending BioEurope...
8th International Neoantigen Summit
YGION Biomedical’s CSO, Dr Anna-Dorothea Gorki is attending the 8th International Neoantigen Summit on June 24-26, in Amsterdam, Netherlands. This conference brings together the global neoantigen community to address key challenges in the...
